SLGL News and Press, Sol-Gel Technologies Ltd. From 12/07/20

- PDUFA Goal Date Set for August 1, 2021 - Potential to be the first acne treatment that contains a fixed-dose combination of benzoyl peroxide and tretinoin NESS ZIONA, Israel, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatolog...

Patented technology for slow release of topical formulations. Potentially the first single-active benzoyl peroxide to be approved as a prescription drug. Two late stage candidates. Funded sufficiently to pull through the anticipated approvals. For further details see: ...

Sol-Gel Technologies (SLGL): Q3 GAAP EPS of -$0.37 beats by $0.09.Revenue of $2.12M (-55.2% Y/Y) beats by $0.3M.Press Release For further details see: Sol-Gel Technologies EPS beats by $0.09, beats on revenue

Epsolay ® PDUFA goal date set for April 26, 2021 Twyneo ® New Drug Application submitted to the U.S. FDA Top-line generic product revenue of $2.1 million in 3Q 2020 In October 2020 , signed an ...

NESS ZIONA, Israel, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies (NASDAQ: SLGL), (“Sol-Gel”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, ...

NESS ZIONA, Israel, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for...

The following slide deck was published by Sol-Gel Technologies Ltd. in conjunction with this Read more ...

VBL Therapeutics reports progress for metastatic colorectal cancer trial VBL Therapeutics ( VBLT ) announced the enrollment of the first two patients for its Phase 2 clinical trial of VB-111. The trial is designed to evaluate the potential of VB-111 used in combination with nivolumab for...

The FDA accepts Sol-Gel Technologies' (NASDAQ: SLGL ) New Drug Application (NDA) seeking approval of topical cream Epsolay (benzoyl peroxide) for the treatment of inflammatory lesions of rosacea, characterized by redness and often small, red, pus-filled bumps on the f...

The FDA accepts for review Sol-Gel Technologies' (NASDAQ: SLGL ) marketing application seeking approval of Epsolay (benzoyl peroxide) topical cream for the treatment of inflammatory lesions associated with an acne-like skin condition called rosacea . More news on: Sol-Gel Technologies...